Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
US Army
Accenture
Farmers Insurance
Citi

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,226,978

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,226,978 protect, and when does it expire?

Patent 8,226,978 protects DSUVIA and is included in one NDA.

This patent has sixty-six patent family members in twelve countries.

Summary for Patent: 8,226,978
Title:Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract: Compositions, methods and systems for administration of small volume sufentanil-containing drug dosage forms to the oral mucosa of a subject are disclosed.
Inventor(s): Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Newark, CA), Hamel; Larry (Mountain View, CA), Poutiatine; Andrew I. (San Anselmo, CA), Rampersaud; Charles (San Francisco, CA), Edwards; Bruce (Menlo Park, CA)
Assignee: AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:12/521,949
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 8,226,978

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF ACUTE PAIN   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,226,978

PCT Information
PCT FiledDecember 28, 2007PCT Application Number:PCT/US2007/089018
PCT Publication Date:July 17, 2008PCT Publication Number: WO2008/085765

International Family Members for US Patent 8,226,978

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 474564   Try a Free Trial
Canada 2636088   Try a Free Trial
Canada 2636115   Try a Free Trial
Canada 2636119   Try a Free Trial
Canada 2673837   Try a Free Trial
Canada 2673856   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Department of Justice
Argus Health
Baxter
Fuji
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.